Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer

Anna Morabito, Beatrice Dozin, Sandra Salvi, Gennaro Pasciucco, Giuseppe Balbi, Stefania Laurent, Simona Pastorino, Franca Carli, Mauro Truini, Paolo Bruzzi, Lucia Del Mastro, Maria Pia Pistillo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Investigation is lacking regarding the clinical impact of human leukocyte antigen (HLA) class I downregulation in breast cancer and results are inconsistent. In this study, we investigated the expression of HLA class I, the heavy chain, and β2-microglobulin (β2-m) by immunohistochemistry in 67 breast carcinomas (BC) and correlated results with clinical-pathologic parameters and patient outcomes. Seventy-six percent of BC were downregulated for HLA class I, whereas downregulation of heavy chain and β2-m was observed in 57 and 46% of BC, respectively. A significant association existed between the absence of tumor necrosis and downregulation of class I and β2-m and between the absence of lymphovascular invasion and patient's age and downregulated class I and heavy chain, respectively. Among the lymph node-positive BC patients, a significantly improved overall survival was observed in those showing β2-m downregulation compared with patients with normal β2-m. This result may correlate with the role of β2-m in regulating cancer cell growth.

Original languageEnglish
Pages (from-to)492-495
Number of pages4
JournalHuman Immunology
Volume70
Issue number7
DOIs
Publication statusPublished - Jul 2009

Fingerprint

HLA Antigens
Down-Regulation
Breast Neoplasms
Neoplasms
Necrosis
Lymph Nodes
Immunohistochemistry
Survival
Growth

Keywords

  • β2-Microglobulin
  • Breast cancer
  • Downregulation
  • HLA
  • Overall survival

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer. / Morabito, Anna; Dozin, Beatrice; Salvi, Sandra; Pasciucco, Gennaro; Balbi, Giuseppe; Laurent, Stefania; Pastorino, Simona; Carli, Franca; Truini, Mauro; Bruzzi, Paolo; Del Mastro, Lucia; Pistillo, Maria Pia.

In: Human Immunology, Vol. 70, No. 7, 07.2009, p. 492-495.

Research output: Contribution to journalArticle

Morabito, Anna ; Dozin, Beatrice ; Salvi, Sandra ; Pasciucco, Gennaro ; Balbi, Giuseppe ; Laurent, Stefania ; Pastorino, Simona ; Carli, Franca ; Truini, Mauro ; Bruzzi, Paolo ; Del Mastro, Lucia ; Pistillo, Maria Pia. / Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer. In: Human Immunology. 2009 ; Vol. 70, No. 7. pp. 492-495.
@article{08f401c769d344008cff1d9b7f8d39f9,
title = "Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer",
abstract = "Investigation is lacking regarding the clinical impact of human leukocyte antigen (HLA) class I downregulation in breast cancer and results are inconsistent. In this study, we investigated the expression of HLA class I, the heavy chain, and β2-microglobulin (β2-m) by immunohistochemistry in 67 breast carcinomas (BC) and correlated results with clinical-pathologic parameters and patient outcomes. Seventy-six percent of BC were downregulated for HLA class I, whereas downregulation of heavy chain and β2-m was observed in 57 and 46{\%} of BC, respectively. A significant association existed between the absence of tumor necrosis and downregulation of class I and β2-m and between the absence of lymphovascular invasion and patient's age and downregulated class I and heavy chain, respectively. Among the lymph node-positive BC patients, a significantly improved overall survival was observed in those showing β2-m downregulation compared with patients with normal β2-m. This result may correlate with the role of β2-m in regulating cancer cell growth.",
keywords = "β2-Microglobulin, Breast cancer, Downregulation, HLA, Overall survival",
author = "Anna Morabito and Beatrice Dozin and Sandra Salvi and Gennaro Pasciucco and Giuseppe Balbi and Stefania Laurent and Simona Pastorino and Franca Carli and Mauro Truini and Paolo Bruzzi and {Del Mastro}, Lucia and Pistillo, {Maria Pia}",
year = "2009",
month = "7",
doi = "10.1016/j.humimm.2009.04.029",
language = "English",
volume = "70",
pages = "492--495",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer

AU - Morabito, Anna

AU - Dozin, Beatrice

AU - Salvi, Sandra

AU - Pasciucco, Gennaro

AU - Balbi, Giuseppe

AU - Laurent, Stefania

AU - Pastorino, Simona

AU - Carli, Franca

AU - Truini, Mauro

AU - Bruzzi, Paolo

AU - Del Mastro, Lucia

AU - Pistillo, Maria Pia

PY - 2009/7

Y1 - 2009/7

N2 - Investigation is lacking regarding the clinical impact of human leukocyte antigen (HLA) class I downregulation in breast cancer and results are inconsistent. In this study, we investigated the expression of HLA class I, the heavy chain, and β2-microglobulin (β2-m) by immunohistochemistry in 67 breast carcinomas (BC) and correlated results with clinical-pathologic parameters and patient outcomes. Seventy-six percent of BC were downregulated for HLA class I, whereas downregulation of heavy chain and β2-m was observed in 57 and 46% of BC, respectively. A significant association existed between the absence of tumor necrosis and downregulation of class I and β2-m and between the absence of lymphovascular invasion and patient's age and downregulated class I and heavy chain, respectively. Among the lymph node-positive BC patients, a significantly improved overall survival was observed in those showing β2-m downregulation compared with patients with normal β2-m. This result may correlate with the role of β2-m in regulating cancer cell growth.

AB - Investigation is lacking regarding the clinical impact of human leukocyte antigen (HLA) class I downregulation in breast cancer and results are inconsistent. In this study, we investigated the expression of HLA class I, the heavy chain, and β2-microglobulin (β2-m) by immunohistochemistry in 67 breast carcinomas (BC) and correlated results with clinical-pathologic parameters and patient outcomes. Seventy-six percent of BC were downregulated for HLA class I, whereas downregulation of heavy chain and β2-m was observed in 57 and 46% of BC, respectively. A significant association existed between the absence of tumor necrosis and downregulation of class I and β2-m and between the absence of lymphovascular invasion and patient's age and downregulated class I and heavy chain, respectively. Among the lymph node-positive BC patients, a significantly improved overall survival was observed in those showing β2-m downregulation compared with patients with normal β2-m. This result may correlate with the role of β2-m in regulating cancer cell growth.

KW - β2-Microglobulin

KW - Breast cancer

KW - Downregulation

KW - HLA

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=67449135854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449135854&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2009.04.029

DO - 10.1016/j.humimm.2009.04.029

M3 - Article

VL - 70

SP - 492

EP - 495

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 7

ER -